Table 2.

HLA-CeD, -DQ2.5 and -DQ8 for all inflammatory bowel disease patients, ulcerative colitis patients, and Crohn’s disease patients, compared with controls

HLA	Controls (n = 577)	IBD (n = 457)	Crohn’s disease (n = 250)	Ulcerative colitis (n = 207)
HLA-CeD	227, 39.34% (95%CI: 35.36%-43.33%)	156, 34.14% (95%CI: 29.78%-38.48%), P = 0.0852	90, 36% (95%CI: 30.05%-41.95%), P = 0.364	66, 31.88% (95%CI: 25.54%-38.23%), P = 0.0571, PF = 11%
HLA-DQ2.5	137, 23.74% (95%CI: 20.27%-27.22%)	99, 21.66% (95%CI: 17.89%-25.44%), P = 0.381	65, 26.0% (95%CI: 20.6%-31.4%), P = 0.4879	34, 16.43% (95%CI: 11.38%-21.47%), P = 0.0287, PF = 8%
HLA-DQ8	101, 17.50% (95%CI: 14.40%-20.60%)	60, 13.13% (95%CI: 10.03%-16.23%), P = 0.054, PF = 5%	28, 11.20% (95%CI: 7.29%-15.11%), P = 0.0217, PF = 7%	32, 15.46% (95%CI: 10.53%-20.38%), P = 0.501
HLA-DQ2.2	131, 22.70% (95%CI: 19.29%-26.12%)	134, 29.32% (95%CI: 25.15%-33.50%), P = 0.022, EF = 9%	85, 34% (95%CI: 28.13%-39.88%), P = 0.001, EF = 15%	49, 23.67% (95%CI: 17.88%-29.46%), P = 0.856

HLA: Human leucocyte antigen; PF: Preventive fraction.